Jim Cramer Says Doximity is “Still Too Expensive”

Core Viewpoint - Doximity, Inc. (NYSE:DOCS) is currently viewed as an expensive stock with disappointing recent performance, leading to a recommendation against buying it at this time [1]. Company Overview - Doximity operates a digital platform that provides medical professionals with tools for collaboration, career management, research updates, documentation, and virtual patient care [1]. Recent Performance - The stock experienced a less than 1% increase since Jim Cramer's comments were aired, indicating a lack of strong market confidence [1]. Analyst Commentary - Jim Cramer expressed that Doximity had a "bad miss" in its recent quarter, which was unexpected for a high-growth company, leading to a negative outlook on the stock [1].